| 今开：53.22 | 昨收：53.22 |
| 最高：53.8 | 最低：52.7 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：1.1837017468E10 |
因塞特医疗(INCY)2023-07-19 04:05
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-042547 Size: 8 KB 网页链接查看全文
因塞特医疗(INCY)2023-07-19 04:05
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-042550 Size: 7 KB 网页链接查看全文
因塞特医疗(INCY)2023-07-19 04:05
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-042549 Size: 7 KB 网页链接查看全文
因塞特医疗(INCY)2023-07-19 04:05
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-042555 Size: 7 KB 网页链接查看全文
因塞特医疗(INCY)2023-07-19 04:05
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-042551 Size: 7 KB 网页链接查看全文
因塞特医疗(INCY)2023-07-19 04:05
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-042548 Size: 7 KB 网页链接查看全文
因塞特医疗(INCY)2023-07-19 04:05
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-042554 Size: 7 KB 网页链接查看全文
因塞特医疗(INCY)2023-07-07 04:05
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-041511 Size: 5 KB 网页链接查看全文
因塞特医疗(INCY)2023-07-07 04:05
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-041507 Size: 5 KB 网页链接查看全文
因塞特医疗(INCY)2023-07-07 04:05
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-041510 Size: 7 KB 网页链接查看全文
JZee03-29 13:32
$因塞特医疗(INCY)$ 这个ruxolitinib软膏外用治疗皮肤病，看目前的走量还是挺有前途的，原来还真不知道jak抑制剂可以治疗白癜风。jak抑制剂外用看起来安全性还不错。专利目前到2031。jakafi本身专利到2028.查看全文
产业链观察01-02 23:39
#药闻简讯# 2024年1月1日，$因塞特医疗(INCY)$ 将 KRAS G12D 抑制剂 （INCB161734） 推进入 1 期：一项评估具有 KRAS G161734D 突变的晚期或转移性实体瘤参与者INCB12的研究，详见：网页链接查看全文
美股滚雪球2023-08-01 08:54
$Replimune Group(REPL)$ 和$因塞特医疗(INCY)$ 达成协议，研究前者的溶瘤免疫疗法RP1与后者的口服PD-L1抑制剂INCB99280联合治疗皮肤鳞状细胞癌(CSCC)。
$百济神州-U(SH688235)$查看全文
医药魔方2023-07-26 10:06
7月24日，Syndax Pharmaceuticals和Incyte共同宣布，抗CSF-1R单抗axatilimab在既往接受过二线及以上治疗后疾病进展的慢性移植物抗宿主病（GVHD）成人和儿童患者中的II期AGAVE-201研究取得了积极的关键数据。
网页链接{点...查看全文
产业链观察2023-07-26 01:35
#药闻简讯# 7月24日，$Syndax制药(SNDX)$ 和$因塞特医疗(INCY)$ 共同宣布，抗CSF-1R单抗axatilimab在既往接受过二线及以上治疗后疾病进展的慢性移植物抗宿主病（GVHD）成人和儿童患者中的II期AGAVE-201研究取得了积极的关键数据。
AGAVE-201研究是一项随机、开放标签的II期临床试验，共纳入241...查看全文
SeekingBiotech2023-07-24 22:03
SNDX and Incyte announced topline data from the pivotal AGAVE-201 trial of axatilimab in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy. The trial achieved its primary endpoint across all cohorts
$S...查看全文
药融云医药大数据2023-05-16 16:11
据CDE官网最新公示，成都苑东生物4类化药磷酸芦可替尼片的仿制药上市申请获受理。2022年，该JAK抑制剂全球大卖了$40亿，国内销售额也同比增长23%，达到4亿。目前，该品种在国内尚无仿制药获批，国内首仿药虚位以待。
截图来源：CDE官网
芦可替尼是由Incyte开发的选择性JAK抑制剂（JAK1/JAK...查看全文
智通财经APP获悉，当地时间6月13日，美国FDA宣布批准礼来(LLY.US)和因塞特(INCY.US)联合开发的口服JAK抑制剂巴瑞替尼(英文商品名Olumiant)上市，用于治疗严重斑秃成人患者。值得一提的是，这是美国FDA批准用于治疗斑秃的首款系统性疗法... 网页链接
智通财经APP获悉，美国FDA于当地时间7月29日扩大了礼来(LLY.US)与因塞特医疗(INCY.US)的baricitinib药物(商用名Olumiant)的紧急适用授权(EUA)。根据修订后的EUA，治疗确诊新冠的住院患者时，baricitinib不需与吉利德科学(GILD.US)的Vekl... 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000879169-24-000069 Size: 5 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000879169-24-000070 Size: 5 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-039366 Size: 24 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000879169-24-000066 Size: 7 KB 网页链接
$因塞特医疗(INCY)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000879169-24-000065 Size: 275 KB 网页链接
$因塞特医疗(INCY)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-038500 Size: 35 KB 网页链接
$因塞特医疗(INCY)$ 10-K/A [Amend] Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000879169-24-000062 Act: 34 Size: 360 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000879169-24-000059 Size: 5 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000879169-24-000058 Size: 5 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000879169-24-000057 Size: 5 KB 网页链接